32 citations
,
May 2023 in “Preprints.org” Skin pigmentation varies due to genetics, UV exposure, and medications, with treatments available but requiring medical advice.
1 citations
,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
3 citations
,
July 2024 in “Frontiers in Pharmacology” Puerariae Lobatae Radix can reduce sebaceous gland size and secretion, potentially treating related skin conditions.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Particulate matter causes inflammation in hair cells, potentially harming hair growth.
29 citations
,
December 2022 in “Journal of Nanobiotechnology” Stem cell vesicles reduced eczema symptoms in mice safely.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
227 citations
,
April 2020 in “Cell” More precise, personalized therapies are needed for autoimmune diseases.
19 citations
,
July 2022 in “PNAS Nexus” Similar treatments might work for different types of scarring hair loss.
3 citations
,
January 2023 in “JEADV Clinical Practice” IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
8 citations
,
May 2025 in “Pharmaceuticals” In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
37 citations
,
November 2017 in “Medical Sciences” Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
2 citations
,
November 2019 in “International Journal of Dermatology and Venereology” Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
1 citations
,
October 2022 in “International Journal of Molecular Sciences” Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.
June 2023 in “Current Issues in Molecular Biology” DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
1 citations
,
October 2021 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for severe alopecia areata show promise but lack standard approval.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
Baricitinib effectively regrows hair in severe alopecia areata cases.